Introduction {#eji3478-sec-0010}
============

Cytotoxic T lymphocyte (CTL) mediated recognition and elimination of infected cells is a major arm of the immune response against intracellular pathogens [1](#eji3478-bib-0001){ref-type="ref"}. Typically, CTLs are CD8+ T lymphocytes, which recognize virus‐derived peptides presented on the surface of infected cells in complex with HLA class I molecules [2](#eji3478-bib-0002){ref-type="ref"}, [3](#eji3478-bib-0003){ref-type="ref"}. Aside from innate and humoral responses, induction of effective CTL responses by vaccination is likely required for protection particularly against pathogens that replicate intracellularly and for which induction of sterilizing immunity is difficult. Examples include the causative agents of malaria, tuberculosis, and acquired immunodeficiency syndrome (HIV/AIDS).

HIV/AIDS continues to be a major global health problem [4](#eji3478-bib-0004){ref-type="ref"}. There is strong evidence that CD8^+^ T cells contribute to the control of acute and chronic HIV‐1 infection in a major way [5](#eji3478-bib-0005){ref-type="ref"}. Understanding the characteristics of the HLA class I‐associated peptidomes on the surface of HIV‐1‐infected cells has the potential to crucially inform the development of effective preventive and therapeutic T‐cell vaccines. Such improved understanding may also provide further insights into allele‐specific binding motifs and more general phenomena such as the protective role of certain HLA alleles [5](#eji3478-bib-0005){ref-type="ref"} and factors that define T‐cell immunodominance [6](#eji3478-bib-0006){ref-type="ref"}.

Recent advances in the technology of nanoflow liquid chromatography tandem mass spectrometry (LC‐MS/MS) allow the direct qualitative evaluation of HLA‐associated peptidomes [7](#eji3478-bib-0007){ref-type="ref"}, [8](#eji3478-bib-0008){ref-type="ref"}. In the context of HIV‐1 infection, cells overexpressing individual viral proteins were analyzed for presentation of viral HLA‐associated peptides [9](#eji3478-bib-0009){ref-type="ref"}, [10](#eji3478-bib-0010){ref-type="ref"} and recently, peptides were purified from soluble HLA‐A molecules secreted from a HIV‐1‐infected T‐cell line [11](#eji3478-bib-0011){ref-type="ref"}. In each case, viral antigen was either delivered by transfection of plasmids encoding selected HIV‐1 proteins or by continuous infection cycles of immortalized cells lines secreting soluble HLA molecules in bioreactors. Despite the limitations of these approaches, they yielded a number of important observations, including identification of a considerable number of previously unmapped, putative T‐cell epitopes, and highlighting the paucity of HIV‐1 peptides within the complex immunopeptidome of the HIV‐1‐infected cell.

Here, we used an immunopurification protocol to specifically isolate and identify a large number of peptides bound to HLA class I complexes from HIV‐1‐infected primary CD4^+^ T cells and C8166 cells (a cell line efficiently infected by HIV‐1) utilizing an LC‐MS/MS analysis workflow.

Results {#eji3478-sec-0020}
=======

Characterization of the HLA class I‐associated immunopeptidome of HIV‐1‐infected cells {#eji3478-sec-0030}
--------------------------------------------------------------------------------------

To prepare infected cells, the human immortalized cell line C8166 (A\*01:01/01:01, B\*08:01/44:02; C\*05:01/07:01) or primary CD8^+^ cell‐depleted PBMC from three HIV‐1‐uninfected individuals (C6 of A\*24:02/29:02, B\*35:03/45:01, C\*04:01/06:02; C7 of A\*11:01/68:01, B\*07:02/27:05, C\*01:02/07:02; and C8 of A\*29:02/30:04, B\*41:01/44:03, C\*16:01/17:01 genotypes) was optimally infected with HIV‐1 IIIB at a multiplicity of infection (MOI) that yielded maximal infection rates of 68.2% for the cell line and 19.8, 21.3, and 22.3% for the primary cell samples C6, C7, and C8, respectively. Infection was estimated by an intracellular anti‐p24 antigen staining [12](#eji3478-bib-0012){ref-type="ref"}, and approximately 10^8^ infected cells were used per analysis. As negative control, uninfected C8166 cells and CD8^+^ cell‐depleted PBMC from C8 were analyzed in parallel. Cells were lysed and a resin‐linked, HLA class I‐specific, conformation‐dependent monoclonal antibody W6/32 was used to capture peptide‐loaded HLA complexes. Noncovalent interactions among the complex components were abolished by acid treatment, eluted peptides were separated by reverse‐phase HPLC from the α‐chain and β~2~‐microglobulin of the HLA complexes and the eluted peptide fractions were analyzed by LC‐MS/MS. Collected spectra were interpreted using PEAKS and MASCOT utilizing a protein database that included translations of all the six open reading frames of the complete genomic sequence and annotated protein sequences of the HIV‐1 IIIB stock used for infections.

A range between 2416 and 6795 unique peptides was identified in the C8166 and C6, C7, and C8 cell samples (Fig. [1](#eji3478-fig-0001){ref-type="fig"}A), of which 75 unique peptides (1.1%) in total were derived from HIV‐1 (Table [1](#eji3478-tbl-0001){ref-type="table-wrap"}); no HIV‐1‐derived peptides were identified in mock‐infected cells. Although the peptides ranged from 5 to 52 amino acids in length, 78--92% of peptides were 8--12 amino acids long and 9‐mers were overall the most abundant species (Fig. [1](#eji3478-fig-0001){ref-type="fig"}B). Long peptides could be originated from HLA complexes in the ER, which are estimated to be 5--10% of the total HLA complex population of the cell [13](#eji3478-bib-0013){ref-type="ref"}. In addition, HLA‐bound peptides longer than 12 and up to 25 amino acids have been characterized in the context of several HLA class I alleles [14](#eji3478-bib-0014){ref-type="ref"}, [15](#eji3478-bib-0015){ref-type="ref"}, [16](#eji3478-bib-0016){ref-type="ref"}.

![HLA class I‐associated peptides from HIV‐1‐infected cells. The human T‐cell line C8166 and primary CD4^+^ cells from three individuals (samples C6, C7, C8) were infected with HIV‐1 for 5--7 days. HLA class I‐associated peptides were purified and analyzed using LC‐MS/MS. (A) The total numbers of unique peptide sequences identified by LC‐MS/MS in each sample from a single immunopecipitation experiment with W6/32 antibody and (B) the length distributions of identified peptides in the C8166 cell line (left) and primary CD4^+^ cells (right) are shown. (C) Motif analysis of all eluted 9‐mer peptides for each of the HIV‐1‐infected samples (Weblogo 3.4 [17](#eji3478-bib-0017){ref-type="ref"}). Known anchor residues for the relevant HLA‐A and HLA‐B subtypes are listed above the graphs for each sample (information from MHC Motif Viewer [37](#eji3478-bib-0037){ref-type="ref"}, [38](#eji3478-bib-0038){ref-type="ref"}). The size of the letter representing the amino acid in the indicated position is scaled according to the frequency of occurrence in the peptide. (D) Schematic overview of all HIV‐1‐derived immunopeptides identified in the samples relative to the position of the HIV‐1 proteins assigned within the viral genome, which are depicted as gray boxes. Numbers above and below the gray bars indicate the nucleotide position of the starts and ends of the regarding HIV‐1 genes using the strain HXB2 annotation (generated using the Los Alamos National Laboratory HIV Sequence Locator Tool). The position of each identified peptide sequence relative to the position in the HXB2 annotation is indicated as vertical gray line in the rectangular panel depicted for each sample.](EJI-46-60-g001){#eji3478-fig-0001}

###### 

HLA class I‐associated peptides eluted from HIV‐1 IIIB‐infected cells

  Name   Peptide                  Sample    HXB2                        Predicted binding   IC50     Rank    Predicted   Reported epitope       Reported HLA allele   PEAKS[f](#eji3478-tbl1-note-0006){ref-type="fn"}   MASCOT[f](#eji3478-tbl1-note-0006){ref-type="fn"}   SM[g](#eji3478-tbl1-note-0007){ref-type="fn"}   ELISPOT[h](#eji3478-tbl1-note-0008){ref-type="fn"}
  ------ ------------------------ --------- --------------------------- ------------------- -------- ------- ----------- ---------------------- --------------------- -------------------------------------------------- --------------------------------------------------- ----------------------------------------------- ----------------------------------------------------
  AF8    ASRELERF                 6         Gag (37‐44)                 ASRELERF            17 110   10.00   C\*04:01    ASRELERF               B\*35;01              23                                                                                                     \+                                              5000
  AA9    ASRELERFA                6         Gag (37‐45)                 ASRELERF            17 110   10.00   C\*04:01    HIVWASRELERFAVNPSL     C\*04;01              19                                                                                                     \+                                              None
  AA11   AEAMSQVTNSA              6         Gag (364‐374)               AEAMSQVTNSA         36       0.05    B\*45:01    AEAMSQVTNS             B\*45;01              39                                                                                                     \+                                              120
  FY9    FLGKIWPSY                6; 7; 8   Gag (433‐441)               FLGKIWPSY           18       0.30    A\*29:02    FLGKIWPSYK             A\*02;01              54                                                 31                                                  \+                                              230
  FI9    FSNSAKSII                6         gp160 (277‐285)             FSNSAKSI            5607     4.00    C\*06:02                                                 27                                                                                                     \+                                              60
  SY9    SFEPIPIHY                6; 8      gp160 (209‐217)             SFEPIPIHY           48       0.80    A\*29:02    SFEPIPIHY              A\*29;02              22                                                                                                     \+                                              120
  AL10   AEGGIISLNL               6         gp160 (688‐697)             AEGGIISL            692      1.50    B\*45:01                                                 25                                                                                                     \+                                              60
  AP9    EEVGFPVTP                6         Nef (64‐72)                 EEVGFPVT            569      1.00    B\*45:01                                                 27                                                                                                     \+                                              None
  AE16   ASRELERFAVNPGLLE         7         Gag (37‐52)                 FAVNPGLL            1676     0.20    C\*01:02    ERFAVNPGLL             B\*27;01              30                                                 37                                                  \+                                              680
  SE15   SRELERFAVNPGLLE          7         Gag (38‐52)                 FAVNPGLL            1676     0.20    C\*01:02    ERFAVNPGLL             B\*27;01              19                                                                                                     \+                                              740
  IK7    IILGLNK                  7         Gag (266‐272)               na                  na       0.00    na          KRWIILGLNK             B\*27;01                                                                 38                                                  \+                                              550
  LE11   LKALGAGATLE              7         Gag (334‐344)               KALGAGATL           2560     0.40    C\*01:02                                                 25                                                                                                     ‐                                               70
  ER9    ELYPLTSLR                7         Gag (482‐490)               ELYPLTSLR           8        0.15    A\*68:01                                                 33                                                 30                                                  \+                                              90
  QL10   QPIQIAIVAL               7         Vpu (2‐12)                  QPIQIAIVAL          85       0.80    B\*07:02    QPIQIAIAAL             B\*07;02                                                                 37                                                  \+                                              None
  VV12   VALVVAIIIAIV             7         Vpu (10‐21)                 VALVVAIIIAI         13 373   7.00    C\*01:02    VVAAIIAIV                                                                                       29                                                  ‐                                               90
  NQ10   NTRIPCRLKQ               7         gp160 (413‐422)             TRIPCRLK            289      0.80    B\*27:05                                                 24                                                                                                     na                                              60
  NR10   NETNGTEIFR               7         gp160 (460‐469)             ETNGTEIFR           7        0.10    A\*68:01                                                 26                                                                                                     ‐                                               60
  RL8    RAAGITAL                 7         gp160 (511‐518)             RAAGITAL            2011     0.25    C\*01:02                                                 23                                                                                                     \+                                              None
  LA10   LGAAGSAVGA               7         gp160 (523‐532)             LGAAGSAV            10 344   9.00    B\*07:02                                                 24                                                                                                     na                                              None
  MV10   MLPLVIGAIV               7         gp160 (684‐693)             LPLVIGAI            125      0.80    B\*07:02                                                 22                                                                                                     na                                              1980
  RR9    RDLVLIVTR                7         gp160 (772‐780)             DLVLIVTR            72       1.50    A\*68:01                                                 35                                                                                                     \+                                              None
  SR9    SVIGWPTVR                7         Nef (9‐17)                  SVIGWPTVR           18       0.50    A\*68:01    SVVGWPAVR              A03                   25                                                                                                     \+                                              60
  QK10   QVPLRPMTYK               7         Nef (73‐82)                 QVPLRPMTYK          89       1.00    A\*11:01    QVPLRPMTYK             A\*03;01; A11         19                                                 25                                                  \+                                              2950
  AK9    AVDLSHFLK                7         Nef (84‐92)                 AVDLSHFLK           13       0.12    A\*11:01    AVDLSHFLK              A\*03;01; A11         35                                                 38                                                  \+                                              1240
  FS8    FLGKIWPS                 8         Gag (433‐440)               FLGKIWPS            16 667   8.00    A\*30:04    FLGKIWPS               A\*02;01              27                                                                                                     na                                              na
  VF8    VQKEYAFF                 8         gp160 (169‐176)             VQKEYAFF            1236     0.50    A\*30:04                                                 19                                                                                                     na                                              na
  VY9    VQKEYAFFY                8         gp160 (169‐177)             VQKEYAFFY           148      0.01    A\*30:04                                                 30                                                                                                     na                                              na
  IY9    IVNRVRQGY                8         gp160 (704‐712)             IVNRVRQGY           238      0.01    A\*30:04    IVNRVRQGY              A30                   22                                                                                                     na                                              na
  GY9    GYFPDWQNY                8         Nef (119‐127)               GYFPDWQNY           347      0.05    A\*30:04    GYFPDWQNY              A24                   44                                                 47                                                  na                                              na
  QN18   QLQPSLQTGSEERRSLYN       C8166     Gag (63‐80)                 GSEERRSLY           197      0.20    A\*01:01    GSEELRSLY              A\*01;01                                                                 25                                                  na                                              None
  SY22   SKKKAQQAAADTGHSSQVSQNY   C8166     Gag (111‐132)               AADTGHSSQV          99       0.25    C\*05:01    KTQQAAADK; NSSKVSQNY   B57; B\*35;01                                                            40                                                  na                                              None
  TY11   TGHSSQVSQNY              C8166     Gag (122‐132)               HSSQVSQNY           278      0.25    A\*01:01    DTGHSNQVSQNY           A33                   16                                                 40                                                  \+                                              5000
  HY9    HSSQVSQNY                C8166     Gag (124‐132)               HSSQVSQNY           278      0.25    A\*01:01    NSSKVSQNY              B\*35;01              33                                                 20                                                  \+                                              None
  PA22   PIVQNIQGQMVHQAISPRTLNA   C8166     Gag (133‐154)               MVHQAISPRTL         1461     1.50    C\*07:01    QAISPRTL               Cw\*07                51                                                                                                     \+                                              1145
  MI8    MQMLKETI                 C8166     Gag (198‐205)               MQMLKETI            923      2.00    B\*08:01    AMQMLKETI              A2                    29                                                 32                                                  \+                                              4380
  VK15   VGEIYKRWIILGLNK          C8166     Gag (258‐272)               EIYKRWIIL           149      0.50    B\*08:01    EIYKRWII               B\*08;01              22                                                 27                                                  na                                              5000
  IK12   IYKRWIILGLNK             C8166     Gag (261‐272)               IYKRWIIL            3655     3.00    C\*07:01    IYKRWIILGLNK           A24                   28                                                 23                                                  na                                              1240
  YK11   YKRWIILGLNK              C8166     Gag (262‐272)               YKRWIILGL           3984     3.00    C\*07:01    IYKRWIILGLNK           A24                   46                                                 39                                                  na                                              400
  KK10   KRWIILGLNK               C8166     Gag (263‐272)               KRWIILGL            3478     3.00    C\*07:01    KRWIILGLNK             B27                   30                                                 24                                                  \+                                              360
  KI11   KRWIILGLNKI              C8166     Gag (263‐273)               KRWIILGL            3478     3.00    C\*07:01    WIILGLNKI; IILGLNKI    na; A2, A3            20                                                 33                                                  \+                                              670
  WK8    WIILGLNK                 C8166     Gag (265‐272)               WIILGLNK            27 259   32.00   A\*01:01    KRWIILGLNK             B27                   25                                                 30                                                  na                                              90
  AW11   AEQASQEVKNW              C8166     Gag (306‐316)               AEQASQEVKNW         12       0.01    B\*44:02    AEQASQEVKNW            B44, Cw5              75                                                 68                                                  \+                                              4390
  AW8    ASQEVKNW                 C8166     Gag (309‐316)               ASQEVKNW            11 596   7.00    B\*44:02    AEQASQEVKNW            B44, Cw5                                                                 64                                                  \+                                              1120
  AM14   AEAMSQVTNSATIM           C8166     Gag (364‐377)               AEAMSQVT            1323     1.50    B\*44:02    AEAMSQVTNS             B\*45;01              34                                                 31                                                  \+                                              60
  SM10   SQVTNSATIM               C8166     Gag (368‐377)               VTNSATIM            1429     2.00    C\*05:01    SQVTNSATI; QVTNSATIM   A2; na                                                                   34                                                  na                                              80
  FF16   FLGKIWPSYKGRPGNF         C8166     Gag (433‐448)               FLGKIWPSY           2677     1.50    A\*01:01    FLGKIWPSYKGRPGN        A2                    42                                                 72                                                  \+                                              240
  KF13   KIWPSYKGRPGNF            C8166     Gag (436‐448)               WPSYKGRPGNF         1249     3.00    B\*08:01    KIWPSYKGR              A\*3101               28                                                 51                                                  \+                                              None
  SQ12   SRPEPTAPPFLQ             C8166     Gag (451‐462)               SRPEPTAPPFL         199      0.20    C\*07:01    EPTAPPEESF             B35, B58              21                                                                                                     \+                                              None
  SG16   SRPEPTAPPEESFRSG         C8166     Gag (451‐466)               PEESFRSG            17 531   10.00   B\*44:02    EPTAPPEESF             B35, B58              57                                                 48                                                  \+                                              410
  EY17   ETTTPPQKQEPIDKELY        C8166     Gag (468‐484)               QEPIDKELY           4181     3.00    B\*44:02    TPSQKQEPI              B35, B53              26                                                 22                                                  \+                                              None
  TY16   TTTPPQKQEPIDKELY         C8166     Gag (469‐484)               QEPIDKELY           4181     3.00    B\*44:02    TPSQKQEPI              B35, B53              48                                                 35                                                  \+                                              70
  PP13   PLTSLRSLFGNDP            C8166     Gag (485‐497)               LTSLRSLF            1684     1.00    A\*01:01                                                 47                                                 30                                                  \+                                              None
  PQ16   PLTSLRSLFGNDPSSQ         C8166     Gag (485‐500)               LTSLRSLF            1684     1.00    A\*01:01                                                 68                                                 37                                                  \+                                              60
  SD9    SLRSLFGND                C8166     Gag (488‐496)               SLRSLFGN            17 464   32.00   B\*08:01    KEMYPLASLRSLFGNDPSSQ   A1; Cw7               22                                                                                                     \+                                              None
  SQ13   SLRSLFGNDPSSQ            C8166     Gag (488‐500)               SLRSLFGNDPS         6984     10.00   B\*08:01    KEMYPLASLRSLFGNDPSSQ   A1; Cw7               67                                                 54                                                  \+                                              60
  LQ12   LRSLFGNDPSSQ             C8166     Gag (489‐500)               LRSLFGNDPSS         26 385   32.00   C\*07:01    KEMYPLASLRSLFGNDPSSQ   A1; Cw7               46                                                 61                                                  \+                                              1470
  RQ11   RSLFGNDPSSQ              C8166     Gag (490‐500)               RSLFGNDPS           23 586   32.00   C\*05:01    KEMYPLASLRSLFGNDPSSQ   A1; Cw7               57                                                 62                                                  \+                                              None
  VY8    VLDVGDAY                 C8166     Pol (263‐270)               VLDVGDAY            57       0.10    A\*01:01    TVLDVGDAY              B\*35;01              23                                                                                                     \+                                              70
  EW10   EELRQHLLRW               C8166     Pol (358‐367)               EELRQHLLRW          29       0.05    B\*44:02    EELRQHLLRW             B44                   48                                                 37                                                  \+                                              None
  DE11   DLVAEIQKQGE              C1866     Pol (479‐489)               AEIQKQGE            4606     3.00    B\*44:02                                                 24                                                                                                     ‐                                               70
  AW11   AEIQKQGQGQW              C8166     Pol (482‐492)               AEIQKQGQGQW         21       0.03    B\*44:02                                                 56                                                 67                                                  ‐                                               940
  AY13   AEIQKQGQGQWTY            C8166     Pol (482‐494)               AEIQKQGQGQW         21       0.03    B\*44:02                                                 68                                                 78                                                  \+                                              620
  YY17   YVDGAANRETKLGKAGY        C8166     Pol (596‐612)               RETKLGKAGY          216      0.40    B\*44:02    RETKLGKAGY             A29                   42                                                 56                                                  \+                                              2140
  SI9    SESELVNQI                C8166     Pol (668‐676)               SESELVNQI           67       0.12    B\*44:02                                                 35                                                                                                     \+                                              None
  LE8    LPPVVAKE                 C8166     Pol (743‐750)               LPPVVAKE            45 152   50.00   A\*01:01    LPPVVAKEI              B\*51;01; B\*07;02                                                       32                                                  na                                              None
  QL10   QNVGKKLSKL               C1866     Pol (867‐876)               NVGKKLSKL           1452     3.00    B\*08:01                                                 28                                                                                                     \+                                              70
  SL9    SAEPVPLQL                C8166     Rev (67‐75)                 SAEPVPLQL           469      0.80    C\*05:01    SAEPVPLQL              B14, Cw8              39                                                 57                                                  \+                                              None
  GQ12   GTSGTQGVGSPQ             C8166     Rev (90‐101)                GTSGTQGV            14 242   7.00    A\*01:01                                                                                                    21                                                  na                                              None
  SP9    SPQILVESP                C8166     Rev (99‐107)                SPQILVES            18 207   32.00   B\*08:01                                                                                                    22                                                  na                                              None
  GW10   GVEMGHHAPW               C8166     Vpu (68‐77)                 VEMGHHAPW           19       0.03    B\*44:02                                                 15                                                                                                     na                                              None
  NY9    NFGPGGAIY                C1866     gp160 (310‐318)             NFGPGGAIY           12 517   6.00    A\*01:01                                                 29                                                                                                     \+                                              None
  YL8    YLKDQQLL                 C8166     gp160 (586‐593)             YLKDQQLL            419      1.50    B\*08:01    YLKDQQLL               A24; B8               23                                                                                                     na                                              260
  NW11   NEQELLELDKW              C8166     gp160 (656‐666)             NEQELLELDKW         68       0.12    B\*44:02                                                 32                                                                                                     \+                                              530
  EL9    ELKNSAVSL                C8166     gp160 (806‐814)             ELKNSAVSL           392      1.00    B\*08:01    QELKNSAVSL             B\*40;01              16                                                                                                     na                                              5000
  SR11   SYALASDAQNR              C8166     3′‐5′ frame 2 (1054‐1064)   SYALASDA            22 998   32.00   C\*07:01                                                 26                                                                                                     na                                              230

HXB2: Position of the identified peptide sequence in the reference strain HXB2.

Predicted binding segment: The segment of the identified sequence that has the highest probability to bind to either of the six alleles present in the regarding sample.

Rank: Percentile rank, 2% defines the threshold for potential epitopes (90% sensitivity and 95% specificity) [20](#eji3478-bib-0020){ref-type="ref"}. Rank values above threshold are highlighted in green.

Reported epitope: Reported epitope in LANL‐HIVDB.

Reported HLA allele: HLA restriction previously reported in LANL‐HIVDB.

PEAKS and MASCOT: Probability score: −10 × lg~10~(*p*) where *p* is the probability that the observed match is a true and not random event.

SM: Comparison of synthetic peptide spectra and experimental spectra; "+" indicates a spectral match, "‐"indicates a mismatch.

ELISPOT: Maximal response of 1/24 HIV‐1‐infected individuals screened for responses to the regarding peptide sequence in an ELISPOT assay (spot‐forming units/10^6^ PBMC). na: not analyzed.
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For the primary infected cell line samples, sequence alignment of all identified 9‐mer peptides broadly confirmed an enrichment of the predicted amino acids in the anchor residue positions for the HLA allele genotype of the regarding sample (Fig. [1](#eji3478-fig-0001){ref-type="fig"}C) [17](#eji3478-bib-0017){ref-type="ref"}.

The eluted HIV‐1 peptides were of the following origins: 38 (51%) were from Gag; 9 (12%) were from Pol; 16 (21%) were from Env; 5 (7%) were from Nef; 3 (4%) were from Rev, and 3 (4%) were from Vpu (Fig. [1](#eji3478-fig-0001){ref-type="fig"}D and Table [1](#eji3478-tbl-0001){ref-type="table-wrap"}). Peptide SR11 (Table [1](#eji3478-tbl-0001){ref-type="table-wrap"}) originates from a protein translated from an alternative HIV‐1 reading frame [18](#eji3478-bib-0018){ref-type="ref"}. Overall, 21 (28%) peptides were derived from conserved regions of the HIV‐1 proteome (up to 6% amino acid variation), which are common to many HIV‐1 isolates and, therefore, attractive vaccine targets [19](#eji3478-bib-0019){ref-type="ref"}. Of the 75 identified HIV‐1 peptide sequences, only 13 (17%) matched previously identified optimal epitopes in the Los Alamos National Laboratory‐HIV Sequence Database (LANL‐HIVDB) and only 9/13 were previously reported for the HLA haplotypes of analyzed samples. For 27 (36%) peptides, either a longer sequence containing the identified peptide sequence or a fragment of the identified peptide was reported in LANL‐HIVDB, and for 18/27 sequences an HLA restriction matching one HLA allele of the haplotype analyzed was reported. A further 9 (12%) peptides were reported with one or two amino acid substitutions. The other 26 (35%) peptides were not previously mapped and were, therefore, considered novel. Notably, peptide FY9 was identified in all three primary infected T‐cell lines irrespective of the distinct HLA haplotypes and may be presented by a noncanonical HLA allele, i.e. HLA‐E.

To experimentally affirm the correct assignment of the fragment spectra to precursor peptide sequences, identified HIV‐1‐derived peptides were synthesized and analyzed under identical conditions by LC‐MS/MS for spectrum matches. Of the 53 tested peptides, spectra of 48 (91%) could be confidently matched to those obtained from HIV‐1‐infected cells (Fig. [2](#eji3478-fig-0002){ref-type="fig"}, Table [1](#eji3478-tbl-0001){ref-type="table-wrap"}).

![Spectral matches for HIV‐1‐derived peptides. HLA‐associated viral peptides sequences were synthesized and measured by LC‐MS/MS under identical conditions as the experimentally identified peptide sequences. Shown here are examples for one peptide sequence identified in each of the primary infected cell samples C6, C7, and C8. Both the experimental spectrum that was detected in the indicated sample and the spectrum acquired from the synthetic counterpart (standard) are plotted relative to each other to illustrate the spectral match. Fragment ions are labeled in the spectra and the regarding molecular fragment is indicated in the peptide sequence above each spectrum. Ions are labeled as follows: b: singly charged N‐terminal fragment ion; y: singly charged C‐terminal fragment ion; ^o^: loss of H~2~O; p: parent peptide ion. The detected mass to charge ratio \[m/z\] of the intact peptide parent ion is stated for each spectrum shown.](EJI-46-60-g002){#eji3478-fig-0002}

Using the NetMHCpan 2.8 MHC binding prediction algorithm and a percentile rank threshold of 2% [20](#eji3478-bib-0020){ref-type="ref"}, [21](#eji3478-bib-0021){ref-type="ref"}, [22](#eji3478-bib-0022){ref-type="ref"}, [23](#eji3478-bib-0023){ref-type="ref"}, 47 (62%) peptides were predicted to bind to one HLA allele expressed in the sample (Table [1](#eji3478-tbl-0001){ref-type="table-wrap"}). Generally, the prediction for binding of longer, nonstandard peptides is more challenging and limited to the identification of nested binding sequences. However, an extensive search of predicted nested binding sequences within the eluted peptide sequences increased the number of predicted binding sequences to 63 (84%).

Peptide‐specific responses in HIV‐1‐infected individuals {#eji3478-sec-0040}
--------------------------------------------------------

A biological validation was performed by testing 70 peptides in interferon (IFN)‐γ ELISPOT assays for recognition by PBMCs from 24 HIV‐1‐infected subjects with variable HIV‐1 disease control. Careful selection of individuals ensured that all HLA alleles, from which HIV‐1 peptides were eluted, were covered. Overall, a median (range) of 4 (0--15) tested peptides were recognized per donor with a median (range) total magnitude of all added responses of 1225 (0--21 470) spot‐forming cells (SFC)/10^6^ PBMCs (Fig. [3](#eji3478-fig-0003){ref-type="fig"}). A total of 23/24 patients shared at least one HLA allele with the cells used for peptide elution and 21/24 individuals responded to at least one of the peptides, whereas only three subjects failed to respond to any peptide (Fig. [3](#eji3478-fig-0003){ref-type="fig"}). One individual without any HLA match still showed recognition of one stimulatory peptide, likely responding through alleles belonging to different HLA supertype as described previously [24](#eji3478-bib-0024){ref-type="ref"}, [25](#eji3478-bib-0025){ref-type="ref"} or through CD4^+^ T‐cell recognition. The median (range) number of peptides recognized per individual was 4.9 (0--15) and 23/70 (32%) tested peptides were not recognized by any individual (with or without matching HLA allele). Peptide AW11 (Gag) was recognized by 12/24 subjects; this is an optimal epitope described in the LANL‐HIVDB restricted by HLA‐C\*05:01.

![T‐cell responses to eluted HIV‐1 peptides identified in HIV‐1‐infected subjects. PBMCs from 24 HIV‐1 positive individuals were screened for T‐cell responses to the identified peptide sequences by determining IFN‐γ output in an ELISPOT assay. For each patient, the number of recognized peptides (breadth of the response) and the total magnitude of T‐cell responses are shown in the graph. The HLA genotype of all six class I alleles for HLA‐A, ‐B, and ‐C is given below each patient ID number. Alleles matching any of the alleles of the C8166 cell line or the three primary cell samples analyzed are highlighted in green. For reference, a heat map illustrating responses to each of the 70 peptide sequences tested is shown below for each patient.](EJI-46-60-g003){#eji3478-fig-0003}

The rest of the eluted peptides were recognized between one and six times. Importantly, most of the observed responses targeted peptides that had not previously been defined as epitopes, and only a small proportion of responses were specific for known optimal epitopes. Of the peptides that did not match any HLA‐binding motif of the corresponding cell line, 50% (6/12) gave T‐cell responses, in contrast to a 71% (41/58) response rate for peptides that did match at least one HLA‐binding motif. For peptides with predicted binding stronger than or equal to 0.1%, 83% (10/12) gave a T‐cell response.

Discussion {#eji3478-sec-0050}
==========

Changes in HLA‐associated peptide presentation have been analyzed in the context of HIV‐1 infection [26](#eji3478-bib-0026){ref-type="ref"} and more recently, HIV‐1‐specific, HLA‐associated peptides have been identified in a model cell line secreting HLA‐A\*11:01 molecules [11](#eji3478-bib-0011){ref-type="ref"}, [26](#eji3478-bib-0026){ref-type="ref"}, providing critical novel information for the definition of T‐cell targets in HIV‐1 infection. However, the ability to define HLA‐class I‐associated, HIV‐1‐derived peptidome directly from HIV‐1‐infected primary cells allows a more precise view of the peptides presented on HIV‐1‐infected cells and facilitates detection of natural T‐cell targets.

In our analyses, 35% of eluted HIV‐1‐derived peptides had not to date been reported to be presented by HLA class I and 83% of the peptides had not been previously mapped to a precise HLA‐binding sequence. Underrepresentation of Pol‐derived peptides from primary infected CD4^+^ cells was notable and concurred with some previous reports [27](#eji3478-bib-0027){ref-type="ref"}, [28](#eji3478-bib-0028){ref-type="ref"}, [29](#eji3478-bib-0029){ref-type="ref"}, these peptides may be less abundantly presented on HLA‐I molecules in infected cells compared to Gag‐derived peptides. However, the number of vaccine‐elicited Pol‐specific CD8^+^ effectors has been shown to correlate with inhibition of HIV‐1 replication in autologous cells at least equally to Gag‐specific responses [30](#eji3478-bib-0030){ref-type="ref"}, [31](#eji3478-bib-0031){ref-type="ref"}. Thirty‐two percent of the eluted peptides were not recognized in subjects used in this study that were naturally infected with HIV‐1. This could be because the viruses with which these individuals were infected deviated from the relevant sequences, or because responses mounted to these peptides had declined to undetectable frequencies at the time of sampling due to viral escape. Alternatively, responses to these peptides may be subdominant to undetectable levels. On the other hand, responses to some peptides may also not have been induced due to a gap in T‐cell repertoire or due to HLA restriction. Nevertheless, vaccination may induce T‐cell responses against these peptides and therefore these sequences remain to be useful targets for T‐cell vaccination.

In conclusion, we demonstrate here that we now have the capacity to delve more deeply into the HLA class I‐associated immunopeptidome of primary infected cells to identify less‐abundant pathogen‐derived peptides. These advances bring us one step further toward identification of T‐cell targets on primary cells isolated from infected individuals in a clinical setting which will be of exceptional importance for the development of personalized immune treatments.

Materials and methods {#eji3478-sec-0060}
=====================

HIV‐1 IIIB virus stock preparation {#eji3478-sec-0070}
----------------------------------

HIV‐1 IIIB (clade B, CXCR4‐tropic) isolate was obtained from the Program EVA Centre for AIDS Reagents, National Institute for Biological Standards and Control (NIBSC) and expanded as described previously [12](#eji3478-bib-0012){ref-type="ref"}. HIV‐1 IIIB viral stocks were prepared by propagation in primary CD4^+^ cells and virus‐containing supernatant was harvested at day 6 postinfection, aliquoted, and frozen at −80°C. Fifty percent tissue culture infectious dose (TCID~50~) was calculated as described previously [12](#eji3478-bib-0012){ref-type="ref"}.

Cell culture {#eji3478-sec-0080}
------------

C8166 cells or CD4^+^ T cells purified from PBMC by magnetic bead selection were stimulated with phytohemagglutinin (5 μg/mL) in RPMI‐1640 medium supplemented with 10% FCS (R10) for 3 days, washed, and infected with HIV‐1 IIIB at a MOI of 0.01. This preselected MOI yielded detectable infection in all wells when tested in the TCID~50~ assay without causing significant cell death, i.e. less 20% lymphocytes stained with Aqua Live/Dead (Invitrogen, data not shown). Infection was achieved by spinoculation for 2 h at 25°C, after which cells were washed twice and cultured at 1.5 × 10^6^ cells/mL in R10 supplemented with IL‐2 (20 IU/mL) for 5--7 days before harvesting the cells. To estimate the percent infection, 0.5 × 10^6^ cells were harvested and stained first with Aqua Live/Dead Fixable stain (Invitrogen), fixed with 4% paraformaldehyde solution/lysolecithin (20 μg/mL) at room temperature and resuspended in cold 50% methanol for 15 min. Further permeabilization was achieved with 0.1% Nonidet P‐40 and cells were then stained with antibodies to HIV‐1‐ Gag p24 (KC‐57‐FITC, Beckman Coulter) followed by antibodies to CD3, CD4, and CD8 conjugated to APC‐Cy7, PerCP, and APC, respectively (BD Biosciences). Samples were acquired on a CyAn flow cytometer and analyzed using FlowJo (version 9.2). If the infection rates were equal or above 20% of CD4^+^CD3^+^ live cells, cells were harvested and lysed using cell lysis buffer (1% Igepal 630, 300 mM NaCl, 100 mM Tris pH 8.0). Intracellular p24 was detected after NP‐40 permeabilization and staining with a HIV‐1 Gag p24‐specific antibody (KC‐57).

HLA class I immunoprecipitation and HPLC fractionation {#eji3478-sec-0090}
------------------------------------------------------

Purification of HLA class I‐bound peptides was carried out as previously described [32](#eji3478-bib-0032){ref-type="ref"}. Briefly, lysates of infected cells were cleared by two subsequent centrifugation steps at 500 × *g* for 10 min and 20.000 × *g* for 30 min. HLA complexes were captured on Protein A‐sepharose beads (Expedeon) cross‐linked to W6/32 antibody (5 mg/mL) [32](#eji3478-bib-0032){ref-type="ref"} at gravity flow and washed using subsequent runs of 50 mM Tris buffer, pH 8.0 containing first 150 mM NaCl, then 400 mM NaCl, and then, no salt. HLA‐peptide complexes were eluted with 5 mL 10% acetic acid. Affinity column‐eluted material was loaded onto on a 4.6 × 50 mm ProSwift RP‐1S column (Thermo Fisher Scientific) and eluted using a 500 μL/min flow rate over 10 min from 2 to 35% buffer B (0.1% formic acid in acetonitrile) in buffer A (0.1% formic acid in water) using an Ultimate 3000 HPLC system (Thermo Scientific). Detection was performed using a variable wavelength detector at 280 nm. Fractions up to 12 min that did not contain ß~2~‐microglobulin were combined and dried.

LC‐MS/MS analysis {#eji3478-sec-0100}
-----------------

Each sample was resuspended in 20 μL buffer A and analyzed both on an Orbitrap Elite (Thermo Scientific) online coupled to an Acquity nano UPLC (Waters) and a TripleTOF 5600 (AB SCIEX) coupled to an Eksigent ekspert nanoLC 400 cHiPLC system. *Orbitrap Elite*: Peptides were separated on a nano Acquity UPLC system (Waters) supplemented with a 25 cm BEH130 C18 column, 1.7‐mm particle size using a linear gradient from 8 to 35% buffer B in buffer A at a flow rate of 250 nL/min for 60 min. Peptides were introduced to an Orbitrap Elite mass spectrometer using a nanoESI source. Subsequent isolation and collision‐induced dissociation was induced on the 20 most abundant ions per full MS scan using an isolation width of 1.5 amu. All fragmented precursor ions were actively excluded from repeated selection for 15 s. *TripleTOF 5600*: Peptides were separated on an ekspert nanoLC 400 cHiPLC system (Eksigent) supplemented with a 15 cm x 75 μm ChromXP C18‐CL, 3 μm particle size using a linear gradient from 8% buffer A to 35% buffer B at a flow rate of 300 nL/min for 60 min. Peptides were introduced to TripleTOF 5600 mass spectrometer and collision‐induced dissociation fragmentation using ramped collision energy was induced on the 30 most abundant ions per full MS scan using unit isolation width 0.7 amu. All fragmented precursor ions were actively excluded from repeated selection for 15 s.

MS data analysis interpretation {#eji3478-sec-0110}
-------------------------------

Raw data were converted to MASCOT generic files using msconvert [33](#eji3478-bib-0033){ref-type="ref"} or ProteinPilot 4.5 [34](#eji3478-bib-0034){ref-type="ref"}. Sequence interpretation of MS/MS spectra were performed using a database containing all annotated human SwissProt entries including translations of all six reading frames of the sequenced HIV‐1 IIIB genome in addition to translations of all known assigned HIV‐1 protein coding regions (GenBank KJ925006) or a database containing all annotated human SwissProt entries (02/2013, 20 253 entries) and all HIV‐1 entries in NCBI (02/2013, 446 954 entries) with PEAKS 7 [33](#eji3478-bib-0033){ref-type="ref"} and MASCOT 2.4 [34](#eji3478-bib-0034){ref-type="ref"}, [35](#eji3478-bib-0035){ref-type="ref"}. The probability score threshold was defined by decoy database searches implemented in the regarding search engines at a general false discovery rate of 5%.

Ethics statement {#eji3478-sec-0120}
----------------

Chronically HIV‐1‐infected individuals were recruited from the HIV Unit in Hospital Germans Trias i Pujol, Badalona (*n* = 16) and Hospital de la Vall d\'Hebron, Barcelona, Spain (*n* = 8). The study was approved by the Institutional Review Board of both participating hospitals and all individuals provided written informed consent before entering the study. PBMC samples were drawn and processed within 4 h after venipuncture and the cells were stored in liquid nitrogen until use.

IFN‐γ ELISPOT assay {#eji3478-sec-0130}
-------------------

IFN‐γ ELISPOT assay was performed as previously described [24](#eji3478-bib-0024){ref-type="ref"}, [36](#eji3478-bib-0036){ref-type="ref"}. A screening for CTL responses was developed using a matrix of 70 eluted peptides from immunoprecipitated HLA class I complexes. Cryopreserved PBMCs from 24 subjects were incubated with the matrix peptide pools in a precoated plate (Millipore, Barcelona, Spain) with anti‐human IFN‐γ monoclonal antibody (Mabtech, Sweden). Cells with R10 medium only were used as negative controls and cells with phytohemagglutinin were used as positive controls. PBMCs were cultured overnight at 37°C, 5% CO~2~ atmosphere, and then washed six times with PBS. The plates were then incubated for 1 h at room temperature with the biotinylated anti‐I IFN‐γ monoclonal antibody (Mabtech) followed by six washes and 1 h incubation with the streptavidin‐coupled alkaline phosphatase (Mabtech). After washing the plate, nitro blue tetrazolium and 5‐bromo‐4‐chloro‐3‐indolul phosphate (Bio‐Rad, Barcelona, Spain) were added for color development. After a short incubation, the reaction was stopped by washing the plate with tap water. The IFN‐γ production was detected as blue spots on the membrane, the spot‐forming units were counted with an automated ELISPOT reader system (CTL, Germany) using ImmunoSpot software package. Responses were defined as positive if they exceeded (i) 50 spot‐forming units/10^6^ PBMC per well, (ii) the mean of negative wells plus three standard deviations, and (iii) three times the mean of the negative well, whichever was higher.
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